Urovant Sciences to Report Second Fiscal Quarter 2020 Financial Results
October 27 2020 - 8:00AM
Business Wire
Urovant Sciences (Nasdaq: UROV) announced today that it will
report financial results for its fiscal quarter ended September 30,
2020 after the close of U.S. financial markets on Monday, November
2, 2020.
Management will host a conference call to discuss Urovant’s
financial results at 1:30 p.m. Pacific / 4:30 p.m. Eastern that
same day. A question and answer session will follow management’s
remarks.
The conference call numbers are (866) 470-1049 for domestic
callers and (409) 217-8245 for international callers. The
conference ID is 8054049.
A replay of the call will be available approximately four hours
after the call and will be accessible for 7 days at (855) 859-2056,
conference ID 8054049. A webcast will be archived on the Investor
Relations page of the Urovant Sciences website immediately after
the call and will be available for 30 days.
About Urovant Sciences
Urovant Sciences is a clinical-stage biopharmaceutical company
focused on developing and commercializing innovative therapies for
urologic conditions. The Company’s lead product candidate,
vibegron, is an oral, once-daily small molecule beta-3 agonist that
is being evaluated for overactive bladder (OAB). Urovant Sciences
reported positive data from the vibegron 12-week, phase 3 pivotal
EMPOWUR study and demonstrated favorable longer-term efficacy,
safety, and tolerability in a 40-week extension study. The Company
submitted a New Drug Application to the FDA seeking approval of
vibegron for the treatment of patients with OAB in December 2019.
Vibegron is also being evaluated for treatment of OAB in men with
benign prostatic hyperplasia (OAB+BPH) and for abdominal pain
associated with irritable bowel syndrome (IBS). Urovant’s second
product candidate, URO-902, is a novel gene therapy being developed
for patients with OAB who have failed oral pharmacologic therapy.
Urovant Sciences, a subsidiary of Sumitomo Dainippon Pharma Co.,
Ltd., intends to develop novel treatments for additional urologic
diseases. Learn more about us at www.urovant.com.
About Sumitovant Biopharma Ltd.
Sumitovant is a global
biopharmaceutical company with offices in New York City and London.
Sumitovant is a wholly owned subsidiary of Sumitomo Dainippon
Pharma. Sumitovant is the majority shareholder of Urovant and
Myovant, and wholly owns Enzyvant, Spirovant, and Altavant.
Sumitovant's promising pipeline is comprised of
early-through-late-stage investigational medicines across a range
of disease areas targeting high unmet need. For further information
about Sumitovant, please visit
https://www.sumitovant.com.
About Sumitomo Dainippon Pharma Co., Ltd.
Sumitomo Dainippon Pharma is among the top-ten listed
pharmaceutical companies in Japan, operating globally in major
pharmaceutical markets, including Japan, the U.S., China, and the
European Union. Sumitomo Dainippon Pharma is based on the 2005
merger between Dainippon Pharmaceutical Co., Ltd., and Sumitomo
Pharmaceuticals Co., Ltd. Today, Sumitomo Dainippon Pharma has more
than 6,000 employees worldwide. Additional information about
Sumitomo Dainippon Pharma is available through its corporate
website at https://www.ds-pharma.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201027005352/en/
Investor and Media Inquiries: Ryan Kubota 949.769.2706
ryan.kubota@urovant.com
Urovant Sciences (NASDAQ:UROV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Urovant Sciences (NASDAQ:UROV)
Historical Stock Chart
From Sep 2023 to Sep 2024